Ancora: Advancing antibodies from the lab to patient treatments
Summary
Ancora Biotech is advancing three bispecific antibody programs aimed at cancer, inflammatory disease, and chronic hepatitis B. The company already has two candidates in clinical studies and plans to move the third into the clinic in 2024. Lightspeed is co-leading a $60 million Series A round with SR One to fund development. The piece also highlights Roland Buelow’s history of building antibody companies and closing major deals, including Teneobio’s acquisition by Amgen.
Funding
Amount
$60.0M
Total raised
Date
June 9, 2022
Announcement date
Investors
Lightspeed, Lightspeed Venture Partners, Ligand Pharmaceuticals
Lead investors
Company
ancorabiotech.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected